Merck & Co., Inc. (MRK)
| Market Cap | 363.09B +75.5% |
| Revenue (ttm) | 66.57B +4.6% |
| Net Income | 3.17B -80.7% |
| EPS | 1.27 -80.4% |
| Shares Out | 2.47B |
| PE Ratio | 113.85 |
| Forward PE | 16.78 |
| Dividend | $3.40 (2.31%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 5,758,516 |
| Open | 145.74 |
| Previous Close | 144.91 |
| Day's Range | 145.32 - 147.65 |
| 52-Week Range | 77.58 - 156.92 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 152.96 (+3.93%) |
| Earnings Date | Oct 29, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $152.96, which is an increase of 3.93% from the latest price.
News
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Merck & Co. Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Transformation is progressing with strong product launches, positive clinical data, and business development driving growth. Pipeline assets like INT and sac-TMT offer significant upside, while LIPFENDRA is positioned for broad access. AI and global innovation are enhancing R&D efficiency.
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'
Merck & Co. Transcript: Wells Fargo 21st Annual Healthcare Conference
Significant progress was reported in portfolio transformation, with projected human health revenues rising to over $70B by the mid-2030s. Oncology and non-oncology pipelines are advancing, with new launches, robust clinical data, and strategic investments supporting long-term growth.
The Big 3: ROST, MRK, AAPL
Don Kaufman (@Theotrade) calls the U.S. Treasury's $6 billion bond buyback plan "nominal" to investors seeking relief as the inflation picture gets wider by the day. However, he sees bearish opportuni...
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
India's Cipla said on Thursday its U.S. unit entered an exclusive partnership with China's Qilu Pharmaceutical to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. market.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference.
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Stephane Bancel, CEO of Moderna , was at a Lebanese restaurant celebrating a friend's birthday late on August 13 when he got the call.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
This article was written by Doug Nathman, with research by his team at Trefis.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that th...
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
Moderna's personalized mRNA cancer therapy, developed with Merck , reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker's blockbuster treatment Keytruda...
Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin...
U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results
The U.S. Treasury is "at least" doubling debt buybacks for longer-dated nominal coupon securities, causing a surge in fixed income activity after yields hit highs not seen in years. Kevin Hincks expla...
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial r...
Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market
Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates.